Clinical trials: Intermediate Risk Prostate Cancer, open to volunteers
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease
Multi-modality therapy that includes a brachytherapy implant improves outcomes in locally advanced prostate cancer when compared to other radiation-based treatments, but is also associated with more adverse side effects.
- Trial name
- OPTiMAL (NCT03836196)
- Testing
- LDR Brachytherapy and External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Safety and Efficacy of Two-step Radical Prostatectomy
The goal of this observational study is to learn about the safety and efficacy of two-step radical prostatectomy in the treatment of low- to intermediate-risk prostate cancer patient with enlarged prostate and severe benign…
- Trial name
- NCT05722392
- Testing
- Two-step Radical Prostatectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as…
- Trial name
- SChLAP/IDC (NCT04176081)
- Testing
- Darolutamide, Degarelix, Radiation Therapy
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
This is a phase II non-blinded randomized controlled trial of image-guided, tumor-focused radiotherapy in patients with intermediate- or high-risk prostate cancer planning to undergo definitive radiotherapy with or without…
- Trial name
- RadTARGET (NCT06990542)
- Testing
- Image-guided tumor-focused radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Prostate Cancer, Localized Prostate Carcinoma
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer.
- Trial name
- MIDAS (NCT07644598)
- Testing
- Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Georgetown University
Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant…
- Trial name
- NCT06613100
- Testing
- Xaluritamig, GnRH Antagonist
- Where
- 9 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Amgen
Prostate Cancer
Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
The study is being done to compare the side effects between two different radiation techniques, standard non-adaptive radiation therapy vs.
- Trial name
- NCT06678126
- Testing
- Prostate and Pelvic Nodes Radiotherapy
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- Scott Tyldesley
Prostate Cancer
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer.
- Trial name
- NCT07860255
- Testing
- Pasritamig
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
Cost-utility of Focal HIFU vs Prostatectomy
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
- Trial name
- EMERHIT (NCT05710861)
- Testing
- F-HIFU, Radical Prostatectomy
- Where
- 20 sites in France, Guadeloupe
- Volunteers
- 346 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
- Trial name
- DARIUS (NCT05346848)
- Testing
- Association of darolutamide and EBRT, Association of ADT and EBRT
- Where
- 10 sites in France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam…
- Trial name
- NCT07332000
- Testing
- aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Candel Therapeutics, Inc.
Prostate Cancer
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.
- Trial name
- NCT07801664
- Testing
- Androgen Deprivation Therapy (ADT), Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health
Prostatic Neoplasms
Dose Escalation For INtraprostatic LEsions
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer.
- Trial name
- DEFINE (NCT05851547)
- Testing
- Prostate SBRT with Focal Boost, Triptorelin Injection
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ottawa Hospital Research Institute
Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume
Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy /radiotherapy in patients with early stage disease.
- Conditions
- Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume, CAPRA SCORE ≤5
- Trial name
- TOPPGUN-RS (NCT07152067)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Prostate Cancer
Spanish Urological Association Registry of Patients on Active Surveillance
Description: Multicentre observational study, not randomized. Ambispective character (retro and prospective). Opened to any member of the Asociación Española de Urología (AEU), public and private medicine.
- Trial name
- NCT02865330
- Testing
- Registry
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Fundación Instituto Valenciano de Oncología
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca